Minerva Neurosciences, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Remy Luthringer
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1601 Trapelo Road Burlington MA United States of America 02451
- IPO Date
- Jul 1, 2014
- CIK
- 0001598646
- Website
- minervaneurosciences.com
- Similar Companies
- Business
- Minerva Neurosciences, Inc. Minerva Neurosciences, Inc. (NASDAQ: NERV) is a clinical-stage biopharmaceutical company focused on the development and commercialization of proprietary product candidates to treat central nervous system (CNS) diseases, including schizophrenia, Parkinson's disease, insomnia, major depressive disorder, and other neurodegenerative disorders; its lead product candidate, roluperidone, targets negative symptoms in patients with schizophrenia through a novel mechanism of action as a serotonin 2A and alpha-2C adrenergic receptor antagonist; additional pipeline assets include MIN-301, a soluble recombinant form of Neuregulin-1b1 protein licensed for Parkinson's disease and other neurodegenerative conditions, as well as earlier-stage candidates like seltorexant for insomnia and depressive disorders and MIN-117 for major depressive disorder. The company leverages randomized, double-blind, placebo-controlled data from prior trials to advance its programs across multiple regulatory jurisdictions, with a strategy emphasizing innovative trial designs tied to patient benefit, selective collaborations for commercialization, and expansion into new indications. Founded in 2003 and headquartered in Burlington, Massachusetts, Minerva Neurosciences operates primarily in the United States with global intellectual property and clinical development expertise targeting unmet needs in CNS therapeutics. In October 2025, the company secured up to $200 million in a private placement financing, including $80 million upfront and additional tranches via warrants, to fund a confirmatory Phase 3 trial of roluperidone (64 mg dose) evaluating the PANSS Marder negative symptoms factor score at 12 weeks, resubmission of its New Drug Application (NDA) to the FDA following prior alignment on trial design, and preparations for a potential U.S. commercial launch if approved; in November 2025, Minerva appointed Dr. Inderjit Kaul, former Senior Vice President of Late-Stage Clinical Development at Bristol Myers Squibb with experience in schizophrenia therapies like Cobenfy, to its board of directors and as a consultant for roluperidone's clinical development, while planning to add up to three more directors with schizophrenia trial expertise and establish a Scientific Advisory Board.
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
Minerva Neurosciences, Inc (NASDAQ:NERV) Sees Significant Growth in Short Interest
Minerva Announces Leadership Transition
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
Minerva Neurosciences Touts Roluperidone Data, FDA-Aligned Trial Plan for Schizophrenia Symptoms
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
Minerva Neurosciences (NASDAQ:NERV) & UCB (OTCMKTS:UCBJY) Head to Head Analysis
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates